belimumab
gsk
['belimumab']
ab#0348 #acr22: meta-analysis of belimumab for cle w or w/o sle
13 studies included: 70% with low risk of bias
bel improved clinical response at w52 vs non-users or 1.44
decrease risk of severe cutaneous flare or 0.51
most studies against placebo group 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land